Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 1997

View Archived Issues

FTC gives go-ahead for Behring Diagnostics-Dade merger

New antitumor agents discovered at Sagami

Squalene synthase inhibitors in development at Sankyo

Substance P antagonists discovered at Kotobuki

Nonpeptide CRF1 antagonist reduces cerebral infarction in rats

Phase IV trial of Redux

Lovenox superiority established in ESSENCE trial

Roche: 1997 half-year highlights

Laserscope receives approvable letter from FDA

InSite Vision initiates phase II study of ISV-120

Celgene receives patent for SelCID

Theratope vaccine advances to phase III trials

U.S. patent allowed for erectile dysfunction therapy

Millennium reports discovery of new MAD-related proteins

Visualine II receives FDA clearance for marketing

Advisory committee will meet to discuss Synovir NDA

Triangle Pharmaceuticals: Q2 1997 highlights

Non-parenteral insulin formulations for treating IDDM

TNF-alpha inhibitors reported by Centocor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
UK Biobank delivers largest metabolomics dataset of 500K profiles
BioWorld Science
It’s the biological resource that keeps on giving, and now UK Biobank has released the final tranche of data on the levels of 249 metabolites in the blood of its...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...